Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | NMT2 | O60551 | 1/20 | 0.50 |
| ▸ | NMT1 | P30419 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6956302 | 0.93 | NPSR1 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL18622640 | 0.86 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL4674995 | 0.83 | CYP2C9 (0.66) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL3546634 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL2781047 | 0.81 | HTR2C (0.62) | HTR2CADRB2APPNOS3NOS1 | |
| SCHEMBL2781509 | 0.81 | HTR2C (0.62) | HTR2CADRB2APPNMT2NMT1 | |
| SCHEMBL7459828 | 0.81 | HTR2C (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL7482397 | 0.81 | HTR1D (0.68) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL3832948 | 0.81 | HTR2C (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL30908918 | 0.81 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| CN-102796075-B | Benzocycloheptenes derivative as well as preparation method and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2014-03-12 | — | — | CN | disclosed |
| CN-101481323-B | Benzocycloheptenes derivatives, preparation method and medical application thereof | POISON MED INST PLA MED ACAD | 2013-11-20 | — | — | CN | disclosed |
| CN-102796075-A | Benzocycloheptenes derivative as well as preparation method and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2012-11-28 | — | — | CN | disclosed |
| WO-2010107605-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7741343-B2 | 6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands | MERCK PATENT GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| CN-101481323-A | Benzocycloheptenes derivatives, preparation method and medical application thereof | POISON MED INST PLA MED ACAD (CN) | 2009-07-15 | — | — | CN | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20080051394-A1 | 6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands | SCHIEMANN KAI | 2008-02-28 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| EP-0683166-B1 | 3-Indolylpiperidines | MERCK PATENT GMBH (DE) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
| US-5693655-A | 3-indolylpiperidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | disclosed |
| WO-1997038692-A1 | BISINDOLES FOR TREATING PAIN OR NOCICEPTION | ELI LILLY AND COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| CN-1114651-A | 3-indolylpiperidine | MERCK PATENT GMBH (DE) | 1996-01-10 | — | — | CN | disclosed |
| EP-0683166-A1 | 3-Indolylpiperidines | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | disclosed |
| CN-85105804-A | Contain 1 of 1H-indol-3-yl, 3-dimethyl-1H-purine-2, the preparation method of 6-diketone | — | 1986-10-22 | — | — | CN | disclosed |
| EP-0177087-A2 | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-09 | — | — | EP | disclosed |
| US-4548939-A | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones | JANSSEN PHARMACEUTICA N. V. (BE) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051394-A1 | 6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands | CHRM1, CHRNA5, CHRNA4 | CYP1A2 1291/4885CYP3A4 1193/4885CYP2D6 2008/4885 |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | CYP1A2 346/4885CYP3A4 496/4885CYP2D6 547/4885 |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | CYP1A2 346/4885CYP3A4 496/4885CYP2D6 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.